Company news
Pepgen Inc. (NASDAQ:PEPG) news
Pepgen Inc. news releases on 6ix. Latest, Aug 6, 2026: PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Press releases & updates
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 6, 2026
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
August 6, 2026
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
May 21, 2026
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 12, 2026
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
March 29, 2026
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
March 3, 2026
PepGen Announces Regulatory Updates on FREEDOM2
March 3, 2026
PepGen to Participate in the Leerink Global Healthcare Conference
March 2, 2026
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
December 9, 2025
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
December 8, 2025
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
November 12, 2025
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 12, 2025
PepGen to Participate in Upcoming Investor Conferences
November 3, 2025
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
October 2, 2025
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters Option to Purchase Additional Shares
September 29, 2025
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
September 26, 2025
PepGen Announces Pricing of $100 Million Public Offering
September 24, 2025
PepGen Announces Proposed Public Offering
September 24, 2025
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
September 24, 2025
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
August 7, 2025
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
May 28, 2025
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
May 20, 2025
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 8, 2025
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025
PepGen Announces Appointment of Two New Directors to its Board
March 31, 2025
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
March 10, 2025
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
March 4, 2025
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
February 24, 2025
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
February 24, 2025
PepGen Announces CONNECT Program Updates
January 28, 2025
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
December 15, 2024
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
November 20, 2024
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 6, 2024
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
October 7, 2024
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
September 18, 2024
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
August 19, 2024
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
August 19, 2024
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 7, 2024
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
July 29, 2024
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
July 1, 2024
PepGen Announces Executive Team Promotions
June 10, 2024
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 13, 2024
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 12, 2024
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 5, 2024
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 3, 2024
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 19, 2024
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
February 6, 2024
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
January 16, 2024
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
January 7, 2024
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
December 17, 2023